Anti-tumor outcome evaluation against non-small cell lung cancer in vitro and in vivo using PolyI:C as nucleic acid therapeutic agent.

In this study, we explored the anti-tumor mechanism and efficacy in vivo of PolyI:C in NSCLC. Our results showed that PolyI:C had the ability to inhibit tumor cell proliferation and promote cell apoptosis by inducing G1 cell cycle block in LL/2 and A549 NSCLC cells. In vivo animal studies also demonstrated that PolyI:C effectively inhibited the tumor growth, suppressed spontaneous metastasis and prolonged the survival time of LL/2 tumor-bearing mice. Moreover, western blotting and immunohistochemistry assays showed that its anti-tumor mechanism was associated with the interference with PI3K/Akt/p53 signaling pathway. Our results confirmed that PolyI:C increased the expression of CD80, CD86 in spleen dendritic cells of tumor-bearing mice and cytokine secretion in healthy mice. Generally, our study suggests that PolyI:C can become a promising anti-tumor agent. PMID: 31105808 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research

Related Links:

BackgroundThe rationality of selective mediastinal lymph node dissection based on lobe ‐specific metastasis is still controversial. The correlation of lymph node metastasis in lobe‐specific lymphatic drainage regions (LSDRs) and non‐LSDRs has not been widely reported. The purpose of this study was to investigate the variables affecting nodal metastasis in non‐LSDRs and to furt her evaluate the rationality of selective lymphadenectomy in clinical stage IA non‐small cell lung cancer (NSCLC) patients.MethodsThe clinicopathological information of 316 patients with clinical stage IA NSCLC who underwent lobectomy with ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Hille Simon A. Joosse Ronald Simon Markus Tiemann Carsten Bokemeyer Martin Reck Sabine Riethdorf Klaus Pantel Sonja Loges Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low detection rate with the established, Food and Drug Administration (FDA)-approved, EpCAM-based CellSearch® System. We tested an epitope-independent method (ParsortixTM system) and utilized it to assess PD-L1 expression of CTCs from...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Contributors : Yan Zhang ; Yongyue Wei ; Jingjing Ben ; Chen QiSeries Type : Expression profiling by arrayOrganism : Mus musculusMetastasis is the key determinant of poor prognosis for advanced-stage NSCLC patients. Although an important contributor to metastasis is cross-talk between tumor-associated macrophages (TAMs) and tumor cells, its regulation is not fully understood. Expressed primarily in macrophages, scavenger receptor A1 (SR-A1) has been associated with lung tumorigenesis. Here, the mechanistic basis for the involvement of SR-A1 in lung cancer prognosis was investigated using population genetics, transcriptomic...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
AbstractPurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) systemic treatments were...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study demonstrates that NSCLC cells resistant to gefitinib (GR cells) displayed a significantly higher microsomal prostaglandin E synthase-1 (mPGES-1) expression and activity than parental cells. Overexpression of mPGES-1/prostaglandin E-2 (PGE-2) signaling in GR cells was associated with acquisition of mesenchymal and stem-like cell properties, nuclear EGFR translocation and tolerance to cisplatin. mPGES-1 inhibition reduced mesenchymal and stem-like properties, and nuclear EGFR translocation in GR cells. Consistently, inhibition of mPGES-1 activity enhanced sensitivity to cisplatin and responsiveness to gefitinib in...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
This study aimed to clarify whether CT-histogram analysis of tumors can be used to classify patients with clinical stage 0-IA non-small cell lung cancer (c0-IA NSCLC) according to pathological lymph node (pN) status.MethodsPredictive factors associated with pN metastasis (pNM) were identified from the derivation dataset including 629 patients with c0-IA NSCLC who underwent complete resection with lymph node dissection (surgeries between 2008 and 2013). The validation dataset including 238 patients (surgeries between 2014 and 2015) were subsequently re-evaluated. Clinico-surgical factors, including CT-histogram parameters o...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm. Dis Markers. 2019;2019:8435893 Authors: Zhu WY, Fang KX, He JY, Cui R, Zhang YK, Le HB Abstract We sought to develop and validate a clinical nomogram model for predicting overall survival (OS) in non-small-cell lung cancer (NSCLC) patients with resected tumors that were 30 mm or smaller, using clinical data and molecular marker findings. We retrospectively analyzed 786 NSCLC patients with a pathological tumor size less than 30 mm who underwent surgery betwee...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
The role of adjuvant therapy in resected non-small cell lung cancer has been a contentious issue for decades. The current standard of adjuvant chemotherapy1 was only proven by the completion of a series of modern international trials when a first set of older trials failed to demonstrate significant benefit.2 The Lung Adjuvant Cisplatin Evaluation meta-analysis of modern trials demonstrated a significant overall survival improvement of ∼5%.3 This does not seem to extend to molecular targeted therapies for resected Epidermal Growth Factor Receptor or ALK+ non-small cell lung cancer because improvement is seen only ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
There has been no recent randomized evidence justifying postoperative radiation therapy (PORT) in patients with non-small cell lung cancer who have undergone complete resection; it is not recommended for routine use, even in patients with mediastinal involvement (pN2).1,2 Adjuvant treatments such as chemotherapy and PORT should be discussed at a multidisciplinary board with complete surgical and pathologic reports, checking whether the nodal exploration was appropriate, the location and number of mediastinal nodes and hilar/intrapulmonary nodes that were resected, and whether resection was complete.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
.
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study